CSTL:NASDAQCastle Biosciences, Inc. Analysis

Castle Biosciences is trading near a key support level with the price just above $24.6, while technical indicators suggest a potential rebound. The RSI is below 30, indicating oversold conditions, and the MACD histogram has turned positive, signaling a bullish momentum shift. Volatility remains elevated at nearly 49% over the past 30 days, but the beta of around 0.7 points to a lower sensitivity to broader market swings.
Fundamentally, the company posted a striking earnings surprise of over 60% and a modest revenue beat, backed by a strong cash position that comfortably exceeds its debt. Despite negative earnings and margins, free cash flow is positive and the DCF fair‑value estimate (~$28) sits well above the current price, implying substantial upside. Analyst sentiment is very positive, with a “strong buy” consensus and price targets near $50, reflecting confidence in the pipeline and recent product data presentations.